Injective Price Boosted by ETF Filing and Phantom Integration

Injective's price surged over 17% as the broader crypto market moved higher. Two key developments contributed to this rally: the proposed ETF filing by 21Shares and Injective's integration with Phantom.

The proposed ETF, which would track the FTSE Injective Index, aims to allocate between 40% and 60% of its INJ holdings for staking. This strategy could generate additional yield from INJ holdings while maintaining flexibility around liquidity management.

The integration with Phantom enables users to hold, trade, borrow, and exchange tokens through the wallet's application and web extension. This expansion of INJ accessibility may reduce friction associated with accessing Injective's trading and tokenization ecosystem.